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The fundamental role of copper and the recognition of its complexes as important bioactive compounds in vitro and in vivo
aroused an ever-increasing interest in these agents as potential drugs for therapeutic intervention in various diseases. The vast
array of information available for their bioinorganic properties and mode of action in several biological systems, combined with
the new opportunities oﬀered by the ﬂourishing technologies of medicinal chemistry, is creating an exciting scenario for the
development of a novel generation of highly active drugs with minimized side eﬀects which could add signiﬁcantly to the current
clinical research and practice. In this paper we attempt to summarize all the available-to-date informationon these issues.
1.Introduction
Copper exhibits considerable biochemical action either as
an essential trace metal or as a constituent of various
exogenously administered compounds in humans. In its
former role it is bound to ceruloplasmin, albumin, and other
proteins, while in its latter it is bound to ligands of various
types forming complexes that interact with biomolecules,
mainly proteins and nucleic acids. The multifaceted role
of copper in biological systems is demonstrated by several
studies. In particular the involvement of copper in human
diseases has been described from a medicinal-chemical [1]
and a biochemical view [2] focusing on the molecular
physiology of Cu transport [3]. Much of the current research
eﬀort is cited on copper homeostasis [4] and its relation to
iron metabolism [5] aswell asthe role ofcopperin biological
processes related to human physiology and pathology [6, 7].
While a lot of the functions that have been proposed to
account for the homeostasis of inorganic noncomplexed
copper in humans have been described [3–5], only a limited
number of review studies have focused on the multiple
biochemical events which couldb ed i r e c t l yi m p l i c a t e di nt h e
use of copper complexes in medicine.
Current interest in Cu complexes is stemming from their
potential use as antimicrobial, antiviral, anti-inﬂammatory,
antitumor agents, enzyme inhibitors, or chemical nucleases.
Markedly, the biochemical action of Cu complexes with
non-steroidal anti-inﬂammatory drugs (NSAIDs) has been
studied[8].NumerousCu(II)complexesofNSAIDsshowing
enhanced anti-inﬂammatory and antiulcerogenic activity, as
well as reduced gastrointestinal toxicity compared to the
uncomplexed drug, have been prepared and structurally
characterized [8]. They comprise a class of potential anti-
inﬂammatory drugs with reduced side eﬀects, and their
mode of action is attributed to their marked superoxide-
dismutase- (SOD-)mimetic activity. Other studies have con-
centrated on the potential chemotherapeutic properties of
copper-based compounds [9, 10]. Moreover, several authors
have brought to attention the antiviral and antibacterial
activity of Cu(II) complexes. For instance, it was shown
that the infectivity of inﬂuenza A virus is reduced after
exposure on copper surfaces [11]. The mechanism of this
process is only partly understood, but it has been speculated
the degradation of the viral nucleic acid takes place after
the intervention of copper ions. In addition, the study and
development of Cu complexes could be helpful in the design
and production of antiviral and antibacterial materials, able
to deactivate HIV or H1N1 viruses [12]a n da n t i b i o t i c -
resistant bacteria, respectively. Towards this direction, a
method of producing copper-impregnated materials that
possess broad-spectrum antimicrobial properties has been
reported [13].2 Molecular Biology International
Despite the fact that the action of copper in humans has
been intensively studied, the clinical picture of copper status
is not always so straightforward, and less is known about
the role of copper complexes in medicine. Yet it is evident
that such compounds could be very important in medicinal
procedures,andtheirrolehasprobablybeenunderestimated.
The purpose of the present work is to review the published
data in reference to the multiple physiological activities of
copper, with particular focusing on the biochemical action
of copper complexes and their applications in medicine.
Moreover, the importance of the existing biomarkers of
copper status will be evaluated.
2.CopperinHumanHealthand Disease
2.1. Copper Homeostasis. Copper in food (organic copper)
is processed by the liver and is transported and sequestered
in a safe manner. Inorganic copper, such as that in drinking
water and coppersupplements, largely bypasses the liver and
enters the free copper pool of the blood directly. This copper
is potentially toxic because it may penetrate the blood/brain
barrier [1].
About 50% of the average daily dietary copper of around
25μmol (1.5mg) is absorbed from the stomach and the
small intestine. Absorbed copper is transported to the liver
in portal blood bound to albumin and is transmitted to
peripheral tissues mainly bound to ceruloplasmin and, to
a lesser extent, albumin. The liver contains 10% of the
total body content of 1200μmol (80mg). Excess copper is
excreted in bile into the gut, and the faecal copper output
(12.5μmol/24h) is the sum of unabsorbed dietary copper
and that reexcreted into the gut [14]. Cu homeostasis is
regulated by alterations in both the absorptive eﬃciency
and biliary excretion in the gut. At low and high intakes,
the eﬃciency of absorption is regulated up and down,
respectively, butis predominantly controlled via endogenous
excretion [15].
Copperisincorporatedintoanumberofmetalloenzymes
involved in hemoglobin formation, drug/xenobiotic metab-
olism,carbohydrate metabolism, catecholaminebiosynthesis
and the cross-linking of collagen, elastin, and hair keratin
as well as in the antioxidant defense mechanism [1].
Moreover, copper-dependent enzymes, such as cytochrome
c oxidase, superoxide dismutase, ferroxidases, monoamine
oxidase, and dopamine β-monooxygenase, function to
reduce reactive oxygen species (ROS) or molecular oxygen
[1]. Symptoms associated with copper deﬁciency in humans
include normocytic, hypochromic anemia, leukopenia, and
osteoporosis. Copper deﬁciency is rarely observed in the
general population [16].
3.CopperandHuman HealthDisorders
3.1. Oxidative-Stress-Related Disorders. Although copper
homeostatic mechanisms play an important role in the
prevention of copper toxicity, exposure to excessive levels
of copper can result in a number of adverse health eﬀects
includingliver andkidneydamage, anemia, immunotoxicity,
and developmental toxicity [17]. Many of these eﬀects
are consistent with oxidative damage to membranes or
macromolecules. Given the capacity of copper to produce
large amounts of reactive oxygen species (ROS), an excess of
Cu could result in oxidative-stress-related health disorders,
many of which can be linked partially to its redox reactivity.
Copper has been suggested to facilitate oxidative tissue
injury through a free-radical-mediated pathway analogous
to the Fenton reaction [18]. By applying the electron
spin resonance (ESR) spin-trapping technique, evidence for
copper-mediatedhydroxyl radical formation in vivo hasbeen
obtained [19, 20]. ROS are produced through a Fenton-type
reaction as follows:
LCu(II)+H 2O2 −→ LCu(I)+ •OOH+H+
LCu(I)+H 2O2 −→ LCu(II) + •OH+ OH
− (1)
where L = organic ligand.
Similar to Cu toxicity, Cu deﬁciency also aﬀects, directly
or indirectly, the components of the oxidant defense system
and as a result increased ROS and oxidative damage to lipid,
DNA,and proteinshave beenobservedinhuman cell culture
models or clinical syndromes of severe copper deﬁciency
[6, 21]. Copper could act as a “double-edged sword” by
inducing DNA damage and also by inhibiting their repair
[22]. Additionally, copper can bind directly to free thiols of
cysteines resulting in oxidation and subsequent crosslinks
between proteins leading to impaired activity [23].
3.2. Aceruloplasminemia. Ceruloplasmin is a copper-
containing glycoprotein produced in the liver that binds
about 95% of the copper in serum. This glycoprotein
presents ferroxidase activity and catalyzes the conversion of
ferrous to ferric iron which is then transferred to transferrin.
A total absence of circulating serum ceruloplasmin
(aceruloplasminemia) could lead to ferrous iron abundance
within both the reticuloendothelial system and parenchymal
cells [24]. It is noteworthy that hereditary ceruloplasmin
deﬁciency(oraceruloplasminemia) isan autosomal recessive
disorder altering iron metabolism. It is accompanied by
mutations of the ceruloplasmin (Cp) allele on chromosome
3q [16]. Manifestations of aceruloplasminemia at the clinical
level are diabetes mellitus, retinal pigmentary degeneration,
d y s t o n i a ,e x t r a p y r a m i d a ls i g n s ,c e r e b e l l a ra t a x i a ,a n d
dementia. Histopathologic studies have presented signiﬁcant
agglomeration of iron in the liver, pancreas, retina, and
central nervous system. Although the pathogenesis of brain
damage in aceruloplasminemia is currently not fully under-
stood, it is well recognized that iron-mediated oxidative
stress could be implicated in neuronal cell death [25].
3.3. Wilson’s Disease (WD). Wilson’s disease is an autosomal
recessive disease of copper metabolism of which the primary
genetic defect is in ATP7B gene [26]. The biological role of
ATP7B gene is to encode a copper-transport protein located
at the trans-Golgi network and to transfer Cu into the
secretory pathway for both annexation into ceruloplasmin
and excretion into the bile [27]. A major contribution toMolecular Biology International 3
pathophysiology of Wilson’s disease is Cu-mediated oxida-
tive damage, activation of cell death pathways, and eventual
leakage of copper into the plasma pool, which ultimately
results in the accumulation of excess copper in extrahepatic
tissues. Notably,thehepaticCuoverload associated with WD
is histopathologically characterized by bulgy hepatocytes,
inﬂammation, and cytoskeletal alterations and ﬁnally leads
to cirrhosis [28]. WD presents severe neurological symp-
toms, but when it is diagnosed in time, it can be treated with
several ways including the use of chelating agents, low-Cu
diets, and high levels of Zn supplements [29].
3.4. The Menkes Disease (MD). The Menkes disease is an X-
linked recessive disorder caused by defects in a gene that
encodes a copper-transporting ATPase (ATP7A) [30]. In
humans, the ATP7A gene product functions as an intracel-
lularpump to transport copperinto the trans-Golgi network
for incorporation into copper-requiring enzymes including
dopamine-β-hydroxylase (DBH) and also mediates copper
exodus from cells. Copper uptake and excretion by the liver
a r en o r m a li nM Da sw e l la sc o p p e re n z y m el e v e l s ,b u tt h e
absorption of copper in the gastrointestinal tract is severely
impaired. The signiﬁcantly decreased intestinal absorption
of copper results in a shortage of exchangeable copper
followed by a deﬁciency of cuproenzymes with important
role in the developmentallevel[31]. It should be emphasized
that the uptake by peripheral tissues is normal; however,
excretion and intracellular copper traﬃcking are disrupted
by mutations in the ATP7A gene. As a result of impaired
copper eﬄux, peripheral tissues in MD patients tend to
accumulate copper in the form of copper metallothionein.
At the clinical level, MD is characterized by progressive
neurological impairment and death in infancy. Because of
the block in intestinal absorption of copper, the major
clinical impact is from copper deﬁciency in the brain of the
developing fetus, leading to severe brain damage [16].
3.5. Alzheimer’s Disease (AD). Alzheimer’s disease is the
most common form of dementia with progressive patterns
of cognitive and functional impairments. Increased levels
of copper in cerebrospinal ﬂuid accompanied by normal
plasma copperconcentrations in patientswith ADhave been
found [32], while other researchers have reported elevated
free copper plasma levels in AD [1]. In a rabbit model of
AD, addition of trace amounts of copper (0.12ppm) to the
drinking water greatly exacerbated the brain AD pathology
and loss of cognition. [33]. Moreover, a community-based
prospective study suggested that high dietary intake of
copperin conjunction with a diet high in saturated and trans
fatsmaybeassociatedwithacceleratedcognitivedecline[34].
A prominent possible involvement of copper in AD
could be via its interaction with amyloid precursor protein
and β-amyloid peptide in the self-aggregating plaques and
neuroﬁbrillary tangles, characteristic of AD, which may
contribute to the pathogenesis of this disorder via cellular
oxidative stress [35]. Copper ions could induce the aggrega-
tion of amyloidogenic peptide and the production of ROS
which oxidize the β-amyloid peptide [1, 36]. Additionally,
current data reveal that there is a relationship between
copper metabolism in Alzheimer’s and prion diseases, but
the precise molecular mechanism is presently unknown
[37]. Nevertheless, recent investigations revealed that copper
prevents both the formation and the accumulation of β-
amyloid plaques in vitro [38]. In addition, it has been
demonstrated that excess copper inhibits β-amyloid peptide
production, while copper deﬁciency can elevate β-amyloid
peptide secretion by either inﬂuencing amyloid precursor
protein cleavage or by inhibiting its degradation [39]. It
should be emphasized that Cu deﬁciency, similar to Cu
toxicity, also results in higher ROS production and oxidative
damage to proteins [6]. Although many questions remain
unanswered, it is widely accepted that in AD there is an
abnormal brain copper distribution with accumulation of
copper in amyloid plaques and a deﬁciency of copper in
neighbouring cells [39]. However, further investigations are
needed to fully understand the role of Cu ions in AD.
3.6. Inﬂammation. Ceruloplasmin acts as an acute-phase
reactive protein to stress and trauma conditions. As a con-
sequence, elevated copper concentrations have been found
in response to inﬂammation, infection, and various chronic
diseases, such as arthritis. Serum copper levels are higher
than normal in varied inﬂammatory diseases in humans
[40]. The higher levels of ceruloplasmin are accountable for
the increased serum copper in the preceding conditions.
Moreover, the anti-inﬂammatory results ofcopperhave been
shown in humans [40]. On the other hand, the acute or
chronic inﬂammation actuates changes on the metabolism
ofcopper,which contributeto alteredserumand tissue levels
[41].The increase ofserumcopperin inﬂammation couldbe
duetothe increase ofceruloplasmin, which isan acute-phase
protein. Itis well recognized that the role ofceruloplasminin
arthritis is to neutralize free oxygen radicals, mainly anion
superoxide, in an attempt to stop the process of turning
chronic [42, 43].
3.7. Cancer. Increased ceruloplasmin and copper levels in
various tissues have been linked to cancer progression [44].
Ceruloplasmin contributes about 90% of serum copper,
which is then elevated secondarily. Moreover, copper deﬁ-
ciency has been evaluated as an anticancer strategy even
though clinical studies have not been especially encouraging
[45]. While the precise role of copper in cancer development
is presently not known, its involvement through ROS
production in oxidative stress is possible. Recently, it was
shown that copper proteins are associated with metabolic
changes in cancer cells [10]a n dm o s ti m p o r t a n t l yp l a ya
signiﬁcant role in angiogenesis by stimulating proliferation
and migration of human endothelial cells [10].
4.BiomarkersforCopperStatus
inClinicalPractice
Although several molecules-indicators have been proposed
and used so far, a sensitive and speciﬁc Cu status biomarker
has yet to be identiﬁed [46, 47]. To be considered as4 Molecular Biology International
a functional index of Cu status, the chosen marker must (a)
respond sensitively, speciﬁcally, and predictably to changes
in the concentration and/or supply of readily available (and
potentially toxic) copper, (b) be accessible for measurement
and measurable, and (c) impact directly on health [17]. It
is estimated that less than 5% of the total copper concen-
tration circulates independently of binding proteins such as
ceruloplasmin. The concentration of protein-free copper is
very low relative to the total serum copper concentration,
and therefore a clinicallysigniﬁcant change in the free copper
concentration may not be detected through measuring total
copper concentrations in serum alone. Because copper is
most toxic in the unbound form, measurement of unbound
copper in circulation would theoretically be the most direct
laboratorytestfordetectingpotentiallytoxiccopperoverload
[48]. For these reasons, a single index, such as total copper
concentration in serum (determined by several standardized
methods, including atomic absorption spectrometry (AAS),
inductively coupled plasma emission spectroscopy (ICP),
and colorimetric methods applied to autoanalyzers), is
inadequate for assessing the total body copper nutriture
of an individual and must be supported by collaborating
evidence [49]. Usually, immunoreactive or enzymatically
measured ceruloplasmin (Cp) levels are used to evaluate the
body storage of copper. Cp levels are a good reﬂector (or
biomarker) to keep copper status in the right therapeutic
window, avoiding clinical copper deﬁciency. The enzymatic
Cp/immunoturbidimetric Cp is a very useful ratio as index
ofcopperstatusratherthanCpenzymaticactivityorCpcon-
centration alone [50]. Additionally, interleukin-2 secretion
from lymphocytes, neutrophil function, phenotypic proﬁles
of lymphocyte subsets, and response of lymphocytes to T
cell mitogens have been proposed [17, 51] as immunological
biomarkers of marginal copper status.
The speciﬁc activity of copper-containing enzymes in
blood cells, such as erythrocyte superoxide dismutase and
platelet or leukocyte cytochrome c oxidase, may be a better
indicator of metabolically active copper stores than the
serum concentration of copper or ceruloplasmin, since the
enzyme activities are sensitive to changes in copper stores
butare notsensitive tofactors notrelated tocoppernutriture
[49].
Despite the fact that the “ideal” index of copper status
in adult humans has not been established yet, certain
novel potential biomarkers that could be analyzed to
screen for copper deﬁciency are currently under evalu-
ation. Dopamine-β-hydroxylase (DBH), a cuproenzyme,
plays a role in the production of noradrenaline. In copper
deﬁciency, DBH activity may be lower, inducing higher
ratios of dopamine to norepinephrine [52]. Peptidylglycine
α-amidating monooxygenase and lysyl oxidase are both
cuproenzymes whose activity or gene expression may be
inﬂuenced by copper deﬁciency [46]. Moreover, there are
also a number of potential biomarkers of copper overload.
High levels of copper are accumulated in the liver where the
excess of copper can lead to damage. Through nonspeciﬁc,
the hepatic aminotransferase enzymes are biomarkers for
liver abnormality due to copper overload. Urinary β2-
microglobulin could additionally be an assisting marker
of copper excess [53]. Copper chaperon for superoxide
dismutase (CCS) has been proposed [46] as a sensitive and
accuratebiomarkersinceitreﬂectsbothdeﬁciencyandexcess
states of Cu. CCS levels in blood erythrocytes and white cells
aredeterminedwithspeciﬁcantibodiesandhavebeenshown
to vary inversely proportional to Cu status [54]. In a recently
published study, a volumetric analytical method has been
proposed to quantify copper complexes [55].
5.CopperComplexesasPotential
TherapeuticAgents
5.1. Binary Cu(II) Complexes. A number of Cu(II) chelate
complexes that exhibit cytotoxic activity through cell apop-
tosis or enzyme inhibition have been reviewed [56]. Such
complexes containing bi-Schiﬀ b a s e sa sl i g a n d sa r ee ﬀec-
tive in reducing tumor size, delaying of metastasis, and
signiﬁcantly increasing the survival of the hosts. Chelates
of curcuminoids show signiﬁcant reduction of solid tumor
volume in mice (P<. 001), while complexes of pyridine-
2-carbohidrazide derivatives inhibit the expression of c-Src,
a nonreceptor tyrosine kinase, which plays a signiﬁcant
role in growth-mediated signaling pathway, thus showing
cytotoxicity against colon cancer cell lines. Similarly Cu(II)
chelates of salclaldoxime and resorcylaldoxime [57]a r e
potent antiproliferative agents, exhibiting strong cytotoxic
eﬀects comparable to that of adriamycin, by inducing cell
cycle arrest and apoptosis. Their action may involve the
inhibition of the enzyme topoisomerase II activity, by pre-
venting dimer formation of the enzyme and its interaction
with DNA [58]. The diverse biological activity of these
complexes compared to one of the widely used platinum
anticancer drugs cisplatin, indicates diﬀerent mechanism(s)
of action, which have not been yet resolved. It is likely that
copper complexes interact with enzymes and inhibit vital
cell functions, rather than interact with DNA and induce
crosslinks.
Binary Cu(II) complexes with a variety of aromatic
molecules coordinated through N, S, or O donor atoms have
been synthesized and tested for biological activity. Some of
them are presented in Table 1.
The complex 2,6-bis(benzimidazo-2-yl)pyridine cop-
per(II) chloride has been shown to exhibit metalloprotease
activity [59]. It binds to bovine serum albumin causing site-
speciﬁc cleavage of the protein when the system is incubated
in atmospheric conditions. This is believed to take place
through binding and activation of molecular oxygen by the
metal. Complexes of carboxamidrazones exhibit enhanced
antiproliferative activity against B16F10 mouse melanoma
cells [60]. It is suggested that the combination of Cu(II)
with carboxamidrazone ligands may facilitate intracellular
transportation and block estrogen receptors. Coordination
of N6-substituted adenines to Cu(II)also results in enhanced
cytotoxic activity against various forms of human cancer
[61]. In this case as well, the resulting Cu(II) complexes
inhibit cyclin-dependent kinases.
Though copper is an essential cofactor for tumor angio-
genesis processes, several Cu(II) binary complexes have beenMolecular Biology International 5
Table 1: Binary Cu(II) Complexes that exhibit biological activity.
Ligand Coordination mode Type of complex a Biological
activity Reference
2,6-bis (benzimidazo-2-yl) pyridine
HN N
N
N
HN
Cu
LCuCl2
or
[LCu(H2O)2(NO3)]+
Protease
mimetic [59]
Pyridyl-2-carboxamidrazone
N
Cu
N
N
N
H2N
LCuCl2 Anticancer [60]
6-(2-chlorobenzyl amino) purine
N
N
Cl
NH
N
NH+
Cu
[(LH)2CuCl3]+
Potent
anticancer,
inhibiting cell
growth of
various types of
cancer
[61]
5-nitrofuran-2-carboxaldehyde
thiosemicarbazone or
thiophene-2-carboxaldehyde
thiosemicarbazone
O
HN
N
Cu
S
R
NO2
R = alkylamino
L2CuCl2 Antiamoebic [62]
4-nitroacetophenone
thiosemicarbazone
N
Cu
S
R
NO2
N
R = CH3NH−,
(CH3)2N−,
N−
L2Cu Antitrypano
somal [63]6 Molecular Biology International
Table 1: Continued.
Ligand Coordination mode Type of complex a Biological
activity Reference
2,4-diiodo-6-(pyridine-2-yl
methylamino) methyl phenolate
Cu HN
N
I
I
O− (L-H)CuCl or
[L(L-H)Cu]+
Proteasome
inhibitor,
apoptosis
inducer
[64]
Pyrolidine dithiocarbamate N
S
Cu
S−
L2Cu
Proteasome
inhibitor,
apoptosis
inducer
[65]
Ciproﬂaxin
(R = )
Enoxacin(R = C2H5-)
N
HN
N
Cu
O
R
F
O
O−
L2Cu Antibacterial [66]
[(5-bromo-2-
hydroxyphenyl)methylidene]
amino-N-(pyrimidin-2-yl)benzene
sulfonamides N
N
N Cu
S
O
O NH
R
R
Br
R = H−,C H 3−
O−
(L-H)2Cu Antibacterial [67]
a(LH) denotes protonated ligand; (L-H) denotes deprotonated ligand.
reported to function as proteasome inhibitors, inducing
apoptosis in various types of human cancer cells. In such
complexes, described as “organic copper compounds” [2],
the metal is coordinated either to neutral heteroatomic
molecules such as phenanthroline or to anionic organic
ligands such as 8-hydroxyquinolinate, pyrrolidine dithiocar-
bamate, or (pyridine-2-ylmethylamino)methyl phenolate. It
is noticeable that the free ligands themselves are not eﬃcient
inhibitors, and complex formation is necessary for the
transportation of copper ions through the cell membrane, in
order to achieve proteasome inhibition [64]. This seems to
be the result of the increasing lipophilicity of the metal upon
ligand coordination.Similarzinc complexeshavebeenfound
to be less-eﬃcient proteasome inhibitors [65].
Copperdeﬁciencycaninhibitangiogenesis,thusprevent-
ing the growth of tumor cells or an inﬂammation to spread.
In this regard the control of copper levels can be potentially
usedasastrategyinthetherapyofcanceroragainst neurode-
generative diseases [68]. The role of copper in angiogenesis
processes is not yet understood, and further research is
needed for this purpose. In order to enhance biological
activity, it has been a common practice to synthesize Cu(II)
complexes of biologically active ligands. Thus complexes
of thiosemicarbazones have been extensively studied in
eﬀorts to synthesize eﬃcient anticancer drugs [9]. Such
complexes were also found to inhibit enzymatic activity and
induce cell apoptosis [10] such activity is usually correlated
with anticancer drug validity. Similarly Cu(II) complexes
of nitrophenone thiosemicarbazones have been found to
exhibit signiﬁcant antitrypanosomal activity in vitro [63].
A number of binary Cu(II) complexes of 2-carboxaldehyde
thiosemicarbazone derivatives [62], quinolone derivatives
[66], and benzenesulfonamide derivatives [67]t h a th a v e
been synthesized, structurally characterized, and tested for
biological activity are cited in Table 1.
In contrast to the large number of Cu(II) complexes
that have been synthesized as potential drugs, Cu(I) ones
are sparse due to the lower stability of the +1 redox state
and their propensity towards oxidation to Cu(II) com-
pounds.BinaryCu(I)complexesoftheformulaeCuLCl,withMolecular Biology International 7
L=N,N -disubstitutedthioureasand[CuL4]+ withL=1,3,5-
triaza-7-phosphaadamantane exhibit moderate cytotoxicity
against various human cell lines [69].
5.2. Ternary Cu(II) Complexes. Numerous mixed ligand
complexesthatcombineoneortwobidentateN,N-andO,O-
coordinated ligands have been synthesized and tested for
biologicalactivity.ChemicalformulaofrepresentativeCu(II)
ternary complexes together with the coordination mode of
various ligands are cited in Table 2. Complexes of the type
[CuLL ]+,w h e r eL= N,N-chelate such as phenanthroline
or 2,2 -bipyridine and L  = N,N- or N,O-chelate such
as acetylacetonate or glycinate (see Table 2), are known
as casiopeinas [70]. They exhibit signiﬁcant antineoplastic
activity in vitro and in vivo, against a variety of tumor cell
lines.
They interact with mitochondria of both healthy and
tumor cells, inhibiting oxidative phosphorylation and res-
piration [70]. In addition they exhibit high aﬃnity towards
DNA binding as well as nuclease activity towards plas-
mid, genomic, and internucleosomal DNA. Degradation is
achieved through the production of reactive oxygen species
(hydroxylradicals)[78].Thecomplexofo-iodohippuricacid
(see Table 2) exhibits both antitumor and nuclease activity.
Inhibition (up to 35%) of lung adenocarcinoma (A549) cell
growth takes place within 24 hours when the complex was
administered in a concentration of 75nM. Healthy cells were
not aﬀected under the same conditions [71].
A number of mixed ligand complexes with Schiﬀ bases
and 2-amino-2-thiazoline, included in Table 2, have been
reported to show signiﬁcant anti-inﬂammatory, antibacte-
rial, and anticancer activity against various cell lines [72].
The biological activity of these complexes does not correlate
with their lipophilicity. Several quinolone mixed ligand
complexes that have been synthesized and structurally char-
acterized [73–76] are also summarized in Table 2.T h e yh a v e
been found [55] to exhibit in vitro antimicrobial activity as
well as concentration-dependent cytotoxicity against human
leukemia cells, with the sparﬂoxacin complex being the most
potent. These complexes were also found to bind in calf-
thymus DNA in an intercalate mode.
A few Cu(I) complexes have been synthesized and tested
in vitro as potential anticancer drugs. Mixed ligand Cu(I)
complexes of triazolylborate and alkyl- or aryl-phosphines
havebeenfoundtobeeﬀectiveagainstA549adenocarcinoma
cells that are resistant to the widely used anticancer drug,
cisplatin [79].
6.Biological Activityof CopperComplexes
Biological screening results of representative binary and
ternary copper complexes are shown in Table 3.
Metalloprotease activity of the complex 2,6-bis(benzim-
idazo-2-yl)pyridine copper (II) chloride was found with
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) with bovine serum albumin in the presence of
oxygen. Albumin undergoes site-speciﬁc cleavage with the
resultant formation of four fragments of molecular weight
49, 45, 22 and 17 kDa [59]. Bridged Cu(II) complexes of
6-(methoxybenzylamino)purines show antioxidant activity
both in vitro and in vivo. Values of IC50 = 0.253 up
to 1.250 μM were reported for the superoxide-dismutase-
(SOD-)mimic activity for the Cu complex in vitro compared
to IC50 = 0.480μM of the native bovine Cu,Zn-SODenzyme,
used as a standard. The pretreatment of mice with Cu
complexes in vivo led to the complete elimination of cyto-
toxic attack of alloxan-induced diabetes and its free radical
metabolites (cytoprotective eﬀect) [80]. Copper complexes
that exhibit high SOD-like activity are potent drugs for
priondiseasessincesuchactivityiscorrelatedwithantisprion
activity. It is known that prion proteins can bind Cu(II) ions
with high speciﬁcity as theypossess a number of coppersites.
Moreover, in the development of prion disease, copper may
modulate the rate of protein misfolding [81].
Bis(5-nitrofuran-2-carboxaldehyde thiosemicarbazone)
copper (II) chloride has been reported [62] to exhibit in
vitro antiamoebic activity against HK-9 strain of Entamoeba
histolyticawithIC50 valuelowerthanthecorrespondingmet-
ronidazole,thedrugofchoiceforamoebiasis(IC50 =0.38μM
and IC50 = 0.34μMv er s usIC 50 = 1.81μM ofmetronidazole).
These results indicate that the metallated thiosemicarbazone
may be a lead molecule in inhibiting growth of E. histolytica.
Bis(4-nitroacetophenone thiosemicarbazone) copper
(II) complexes exhibit antitrypanosomal activity in vitro
against the epimastigote form of Trypanosoma cruzi. They
presented less ID50 value (the dose that inhibits 50% of
T.cruzi growth) than their corresponding thiosemicar-
bazones (ID50 = 0.056μMf o rt h eb e s ta n t i - T.cruzi copper
complex versus ID50 = 0.28μM) [63].
Pyrrolidine dithiocarbamate complexes of Cu(II) were
reported to cause the inhibition of the proteasome (cancer
cells are more sensitive to proteasome inhibition than
normal cells) in vitro against LNCaP prostate cancer cells
using two assays as indicators of proteasome inhibition:
(a) the chymotrypsin-like activity assay and (b) a West-
ern blotting analysis performed by antiubiquitin antibody
for the accumulation of ubiquitinated proteins [82]. The
copper complexes resulted in low levels of the proteasomal
chymotrypsin-like activity and the accumulation of ubiqui-
tinated proteins. In contrast, copper or the free ligand alone,
was incapable of inhibiting the proteasome. In addition
pyrrolidine dithiocarbamate-copper complexes were found
[82] to suppress the proliferation of BE(2)C cells, a human
neuroblastoma cell line, with an IC50 = 8.0μM, which
is more potent than cisplatin (IC50 = 80μM). A chelate
Cu(II) complex of N-pyridinobenzamide-2-carboxylic acid
(PBCA)hasbeentestedinvivoforanti-inﬂammatory activity
[83]. The complex shows a greater decrease (26.5%) in
inﬂammation compared with free PBCA (20.2%) against the
cottonpellet granuloma pouch testin rats(thesubcutaneous
implantation of a cotton pellet into a rat results in the
formation of a granuloma at the site of the implant).
The neutral bimetallic complex [Cu2(ibuprofen)4]w i t h
the bridged ligand 2-(4-isobutylphenyl)propionate (ibupro-
fen) exhibits antiulcerogenic in vivo activity as estimated for
gastric irritation in rats [84]. Rats treated with ibuprofen
exhibited a lesion index of 597 ± 43, while markedly lower8 Molecular Biology International
Table 2: Coordination modes of organic ligands in ternary Cu(II) complexes.
Ligands Coordination mode of ligand L Type of complex Biologicalactivity Reference
L: acetylacetone
L : phenanthroline
Cu
O
O−
[LCuL ]+ Anticancer [70]
L: glycine
L : phenanthroline
Cu
NH2
O
O− [LCuL ]+ Anticancer [70]
L: o-iodohippuric acid
L : phenanthroline NH
O
Cu O I
O− [LCuL
 
2]+ Anticancer [71]
L: Schiﬀ base of
diethylenetriamine
L : 2-amino-2-thiazoline
N
S
X
X
N
N
Cu
N
H2N
X = O,S,NH
LCuL Cl2
Anticancer, antibacterial,
anti-inﬂammatory [72]
L: oxolinic acid
L : phenanthroline
N
Cu
O
C2H5
O O
O
O−
LCuL Cl Antibacterial [73]
L: propyl-norﬂoxacin
L :2 , 2  -bipyridineor
phenanthroline
Z N
Cu
O
R Y
F
O
X
R = C2H5−,
X = H, Y = H,
O−
LCuL Cl
Antibacterial, DNA
intercalator, anticancer,
nuclease mimetic.
[74, 75]
N N C3H7 Z =
L: sparﬂoxacin
L :2 , 2  -bipyridine
R = ,
X =− NH2,Y= F, LCuL Cl Antibacterial, DNA
intercalator, anticancer.
[76]
N HN
CH3
CH3
Z =
L: peﬂoxacin
L’: 2,2 -bipyridyl-amine
R = C2H5-, X= H, Y= H,
CH3 N N Z = LCuL Cl Antibacterial, DNA
intercalator, SOD mimetic. [55]
L: gatiﬂoxacin
L : phenanthroline or
2,2 -bipyridylamine
N HN
CH3
Z =
R = ,
X = H, Y = CH3O−,
LCuL Cl Antibacterial, DNA
intercalator, SOD mimetic [55]Molecular Biology International 9
Table 2: Continued.
Ligands Coordination mode of ligand L Type of complex Biologicalactivity Reference
L:
N,N -bis(4-methylphenyl)
sulfonyl ethylenediamine
L : phenanthroline
N
N
Cu
S
SO O
O O
CH3
CH3
LCuL
 
2 Nuclease mimetic [77]
Table 3: Inhibitory eﬀects of selected copper complexes.
Complex Biologicalin vitro activity IC50
a,b (μ) Reference
Bis(4-nitroacetophenone
thiosemicarbazonat) copper(II) Anti-trypanosomal Trypanosoma cruzi 0.056c
(0.28)c [63]
Bis(5-nitrofuran-2-carboxaldehyde-N4-
ethylpiperidine thiosemicarbazone)
copper(II) chloride
Antiamoebic HK-9 strain of
Entamoeba histolytica
0.34
(2.68) [62]
Bis(thiophene-2-carboxaldehyde-N4-methyl
benzyl thiosemicarbazone) copper(II)
chloride
Antiamoebic HK-9 strain of
Entamoeba histolytica
0.21
(1.21) [62]
(2-acetylpyridine)pyridine-2-
carboxamidrazone copper(II)
chloride
Antiproliferative Mouse melanoma cell
line B16F10.d 6.8 [60]
Cu2(μ-L)2(μ-Cl)2L2Cl2
L= 6-(2-chlorobenzylamino) purine Antitumor
Mouse melanoma
B16FO 8.2(85) [61]
Human malignant
melanoma G361
20.0
[61]
(95)
Human osteogenic
sarcoma HOS 23 (>100) [61]
Human breast
adenocarcinoma
MCF7
24(>100) [61]
Tetra(N-methyl-1,3,5-triaza-7-
phosphaadamantanecopper(I) tetraﬂuoro
borate
Antitumor
Cervix tumor (HeLa) 7.6 [69]
Colon tumor
(HCT-15) 19.2 [69]
Lung tumor (A549) 8.5 [69]
Melanoma (A375) 16.4 [69]
Bis(triphenylphosphine),
dihydridobis(3-nitro-1,2,4-triazolyl)borate
copper(I)
Antitumor
Promyelocytic
leukemia (HL60) 4.8 [79]
Cervix carcinoma
(A431) 6.7 [69]
Lung tumor (A549) 1.5 [69]
Melanoma (A375) 16.4 [69]
aValues refer to the most active copper (II) complex tested. Half- maximal inhibitory concentration (IC50) is a quantitative measure of the eﬀectiveness of a
compound in inhibiting a biological function as it indicates how much of a particular substance is needed to inhibit a given biological process.
bValues in parenthesis refer to the free ligand.
cThese values refer to inhibitory dose (ID50): dose that inhibits 50% of Trypanosoma cruzi growth.
dThe exponentially growing cells were counted by haemocytometer using the Trypan blue exclusion method to quantify cell viability.10 Molecular Biology International
lesion indices 290 ± 31 were observed for rats treated with
the copper-ibuprofenato complex. The copper complex was
more eﬀective in the protection of severe intensity ulceration
than the oral administration of the parent drug (free
ibuprofen). The Cu (II) chelates with quinolone derivatives
cited in Tables 1 and 2 exhibit antibacterial activity in vitro
againstStaphylococcusaureusATCC25923andStaphylococcus
aureus ATC57. The best antibacterial copper complex [66]
shows a minimum inhibitory concentration (Andrews 2001)
MIC = 0.5μg/mL versus free ciproﬂoxacin hydrochloride
with MIC = 1μg/mL.
Aiming at the synthesis of potent anticancer drugs, bin-
uclear copper(II) complexes of pyridyl-diamines, as well as
mixed-ligand acetylacetone/quinoxaline complexes exhibit-
ing nuclease and apoptosis-inducing activity, have been
reported recently [77, 85]. In addition the antitumor activity
of Schiﬀ-base copper(II) complexes has been investigated
[86, 87]. The evaluation of a new thiosemicarbazone Cu(II)
chelate was reported to induce tumor growth inhibition
both in vitro and in vivo, through oxidative/endoplasmic
reticulum stress [88].
7.Conclusions
Developing an integrated picture for the role of copper and
its complexes in medicine is a challenging task that awaits
further exploration. Copper ions are considered as multi-
functional participating in a broad spectrum of intracellular
processesundernormalandpathologicconditions.However,
many questions remain unanswered. Further experimental
and clinical studies would aid at unraveling their prominent
activities, thus discovering eﬀective Cu biomarkers and
generating new options for early intervention in copper-
related health disorders. Copper complexes described in
the present work show a diverse in vitro biological activ-
ity, ranging from antibacterial and anti-inﬂammatory to
cytostatic and enzyme inhibitory. At molecular level such
complexes interact directly with proteins and DNA, leading
to dysfunction and cleavage of the macromolecular struc-
ture, or indirectly producing ROS that attack and degrade
biomolecules.
S i n c eD N Ai sap o t e n tt a r g e to fc y t o s t a t i cd r u g s ,t h e
eﬀect of copper compounds on DNA functionality is very
important. The ability of Cu(II) complexes to bind to DNA
and exhibit nuclease activity in the presence of reducing
agents is well established [89]. DNA degradation is believed
to take place through a Fenton-type reaction in which ROS
are produced. The type of organic ligands in such copper
complexesseemstoaﬀectandregulatetheiractivity. They(a)
neutralize the electric charge of the copper ion, (b) increase
thelipophilicityofthecomplexfacilitatingtransportthrough
cell membrane, and (c) intercalate to DNA or interact
noncovalently with proteins. The eﬀect of ligand chelation
may also be of importance for the biological activity of the
complexes, whose exact role has not been elucidated yet.
Spatial geometry of the complex and the structure of the
ligand inﬂuence to a lesser extent the activity of the complex.
The biologicalactivity ofthe ligand is usually increased upon
complexformation, butevidenceofasynergic eﬀectbetween
the metal and the organic ligand is still lacking.
Inconclusion,noveltreatmentoptionsthatinterferewith
copper complexes have been proposed in experimental sys-
tems, albeit their eﬀectiveness in clinical practice remains to
befurtherinvestigated.The greatpressure forproducingnew
eﬀective treatment options in medicine should not surpass
the necessity for careful, rationally designed randomized
studies evaluating the most promising copper complexes as
therapeutic pharmaceuticals.
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